Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.
about
Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical ImplicationsThe distinctive nature of adenocarcinoma of the lungGenetic instability in the tumor microenvironment: a new look at an old neighborFocal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung CancerPI3K and cancer: lessons, challenges and opportunitiesConcurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer.Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression.Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidenceMeta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations.Detection of the epidermal growth factor receptor, amphiregulin and epiregulin in formalin-fixed paraffin-embedded human placenta tissue by matrix-assisted laser desorption/ionization mass spectrometry imaging.Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib.Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategiesCharacteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patientsCYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer.JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.Surgery for NSCLC in the era of personalized medicine.Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications.Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity.Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance.Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms.IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells.Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.The P21-activated kinase expression pattern is different in non-small cell lung cancer and affects lung cancer cell sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond.Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression.The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.Molecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets.Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition.Acquired resistance L747S mutation in an epidermal growth factor receptor-tyrosine kinase inhibitor-naïve patient: A report of three cases.Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: evidence based on recent phase III randomized trials.Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-LetterLong non-coding RNAs associated with non-small cell lung cancer.Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines.
P2860
Q26741318-764C9025-23B1-4663-9300-03D2707EC58EQ26781159-AEF92235-8520-48DC-A176-C18104658DF8Q26801374-D6972178-DA6E-47CF-A2C1-47A4D1B00168Q28550689-B764C28E-E95E-49D9-9B00-503BCDF306EEQ30080017-6CFC6337-7900-416D-B91B-6392CE9D139AQ33648747-F8EF5CF9-480F-4481-BD2B-1256BE3BB2A5Q33677872-ABC2BA6B-041A-449D-9FD2-CA5E8BB6F5DBQ34011705-A0810A01-ACE0-421D-91E9-31A5058E6827Q34449385-CD42ED07-8B88-4B5D-8FD9-F4CC6F8B7715Q34809415-40A39649-B5CB-48FD-966D-EF286E3B9B1FQ35152542-C749D008-3373-4112-8F1B-D2157B98722BQ35602423-DA3EF450-1D67-4B88-9B7A-A445C50C71EDQ36099734-5C37EF6D-5F6A-4CB8-AA61-C758A9610661Q36351290-38D9357C-0E56-465F-AC9D-43684A216BEDQ36850900-6379CEB8-3836-4113-A2C0-F9CAC7FE8C0BQ36921093-86737158-6A31-405F-8966-A2FF3B9B625EQ37352553-5C1A45C1-3798-49F7-A566-56F0C3DBF4A5Q37572972-1DD0A9B3-23D4-4018-BC13-64648D77263DQ37687075-6BF5BAD5-C833-4E9B-8F45-B6037431A95CQ37717519-E1092DEB-DC72-45FB-A97F-918860BC0C8EQ38084427-EC1EC0AB-A7BE-423E-B26E-FB10F90B5E20Q38087239-D962F269-A52A-4C8B-8AAC-C4E847E1AAE2Q38486882-CC5224EE-889D-4770-B7A6-36F478C71AC4Q38504491-B3A84552-8CA3-4852-AEFE-A5DA1D48AEFDQ38682189-8BD43F50-6AB1-4E62-8361-B56981798E6AQ38707122-0EC08E12-97F9-4649-BAF4-D64F054B3855Q38745430-47E31D94-F107-4012-BF40-444CF4AEC5ADQ38746756-A36A8643-AD5D-4D90-BFCF-C884E07386BCQ38798826-0D501491-D629-4321-9DCF-C14F20D7BF0DQ38956309-10880615-3EB9-4EA2-9264-8AD17E3213FFQ39002233-30A561DE-A7D0-4A46-90AB-973F35A6F657Q39031210-8C13C7E1-E33C-434E-A7C3-4FCDCE6F7E4BQ39172297-B935F7BC-73DA-47F7-9D7C-244E3E271F4DQ39281214-554D0957-C668-4542-9C35-0F13F1B81AA4Q41563298-EF5A7755-1A24-4573-BB82-C4BA68276A18Q41852971-0D2DF3CE-DE05-4064-8AA7-4483EBF0B5ECQ42120519-878ECA9C-069E-43FB-BBA5-212AC147FC82Q42316038-91C8A08A-2E68-4C0C-9CBB-EA1958F3BB45Q42366666-D9967FC9-37DB-4C7F-8FE8-0B06FB32AB4AQ47098234-318CB17A-9EB1-4154-931B-FABEE1C2329C
P2860
Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Acquired resistance mechanisms ...... rsity, ductility, and destiny.
@en
type
label
Acquired resistance mechanisms ...... rsity, ductility, and destiny.
@en
prefLabel
Acquired resistance mechanisms ...... rsity, ductility, and destiny.
@en
P2860
P1476
Acquired resistance mechanisms ...... rsity, ductility, and destiny.
@en
P2093
Hiroshi Mizuuchi
Kenichi Suda
P2860
P2888
P304
P356
10.1007/S10555-012-9391-7
P577
2012-12-01T00:00:00Z
P6179
1012103703